You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR2b, FGFR2, FGFR, bladder neoplasms, esophageal cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

Recruiting
  • Metastatic Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • FGFR Testing
  • Calgary, Alberta, Canada
  • +6 more
Nov 8, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York

Recruiting
  • Advanced Solid Tumor
  • +13 more
  • Duarte, California
  • +3 more
Oct 25, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Breast Cancer Trial in Tianjin (Pemigatinib Pill)

Recruiting
  • Breast Cancer
  • Pemigatinib Pill
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
Sep 26, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Bladder Cancer Trial in Vandœuvre-lès-Nancy (Urine collection (150ml), Blood sample (20 ml))

Recruiting
  • Bladder Cancer
  • Urine collection (150ml)
  • Blood sample (20 ml)
  • Vandœuvre-lès-Nancy, France
    Institut de Cancérologie de Lorraine
Mar 23, 2022

Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Cholangiocarcinoma
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Receptors, Fibroblast Growth Factor
  • Erdafitinib Intravesical Delivery System
  • Kanagawa, Japan
  • +3 more
Jan 27, 2023

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)

Not yet recruiting
  • Advanced Solid Tumor
  • +2 more
  • Palo Alto, California
  • +9 more
Aug 2, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Endometrial Cancers With FGFR2 Mutations Trial (FP-1039)

Withdrawn
  • Endometrial Cancers With FGFR2 Mutations
  • (no location specified)
Dec 9, 2021

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Phoenix, Arizona
  • +36 more
Jan 27, 2023

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Breast Cancer Trial in Guangzhou (Fulvestrant plus Anlotinib)

Recruiting
  • Breast Cancer
  • Fulvestrant plus Anlotinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 16, 2021

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022